Trends in safety pharmacology: Posters presented at the annual meetings of the Safety Pharmacology Society 2001-2010

Journal of Pharmacological and Toxicological Methods

Volumn 64, Issue 1, 2011, Pages 102-110

  Redfern, William S ^a   Valentin, Jean Pierre ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Guinea pig; QT; Regulatory guidance documents; Safety pharmacology; Translation

Indexed keywords

AUTOMATION; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; DRUG ABUSE; DRUG DEPENDENCE; DRUG DEVELOPMENT; DRUG SAFETY; GASTROINTESTINAL TRACT; INFORMATION DISSEMINATION; KIDNEY; PHARMACOLOGICAL SCIENCE; PRACTICE GUIDELINE; QT INTERVAL; RESPIRATORY SYSTEM; REVIEW; RISK ASSESSMENT; SAFETY PHARMACOLOGY; TREND STUDY;

ANIMALS; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; HUMANS; SOCIETIES, PHARMACEUTICAL;

CAVIA;

EID: 79961012132     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2011.05.003     Document Type: Review

References (36)

1. Anon. Japanese Guidelines for Nonclinical Studies of Drugs Manual, Pharmaceutical Affairs Bureau. Japanese Ministry of Health and Welfare 1995, 71-80. Yakugi Nippo.
2. Anon. ICH S6: Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals 1997, Available at:. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S6_R1/Step4/S6_Guideline.pdf.
3. Anon. ICH S7A: Safety Pharmacology Studies for Human Pharmaceuticals Available at:. http://www.ich.org/cache/compo/276-254-1.html.
4. Anon. ICH S7B: The Non-clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) By Human Pharmaceuticals Available at:. http://www.ich.org/cache/compo/276-254-1.html.
5. Anon. ICH E14: The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Available at. http://www.ich.org/cache/compo/276-254-1.html.
6. Anon. Guideline on the non-clinical investigation of the dependence potential of medicinal products Available at:. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003360.pdf.
7. Anon. Addendum to ICH S6: Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals S6 (R1) Available at:. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S6_R1/Step2/S6_R1_Step2_Guideline.pdf.
8. Anon. ICH S9: Nonclinical evaluation for anticancer pharmaceuticals Available at:. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S9/Step4/S9_Step4_Guideline.pdf.
9. Anon. Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3(R2) Available at:. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/M3_R2/Step4/M3_R2__Guideline.pdf.
10. Baldrick P. Juvenile animal testing in drug development-is it useful?. Regulatory Toxicology and Pharmacology 2010, 57:291-299.
11. Bass A.S., Cartwright M.E., Mahon C., Morrison R., Snyder R., McNamara P., Bradley P., Zhou Y.-Y., Hunter J. Exploratory drug safety: A discovery strategy to reduce attrition in development. Journal of Pharmacological and Toxicological Methods 2009, 60:69-78.
12. Bass A.S., Kinter L.B., Williams P. Origins, practices and future of safety pharmacology. Journal of Pharmacological and Toxicological Methods 2004, 49:145-151.
13. Bass A.S., Vargas H.M., Kinter L.B. Introduction to Nonclinical Safety Pharmacology and the Safety Pharmacology Society. Journal of Pharmacological and Toxicological Methods 2004, 49:141-144.
14. Bass, A.S., Vargas, H.M., Valentin, J.P., Kinter, L.B., Hammond, T.G., Wallis, R., Siegl, P.K.S., Yamamoto, K. (in press). Safety pharmacology in 2010 and beyond: survey of significant events of the past 10 years and a roadmap to the immediate-, intermediate- and long-term future. In recognition of the tenth anniversary of the safety pharmacology society. Journal of Pharmacological & Toxicological Methods.
15. Car B. Enabling technologies in reducing drug attrition due to safety failures. American Drug Discovery 2006, 1:53-56. (June/July).
16. Hanson L.A., Bass A.S., Gintant G., Mittelstadt S., Rampe D., Thomas K. ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation. Journal of Pharmacological and Toxicological Methods 2006, 54:116-129.
17. Hauser D.S., Stade M., Schmidt A., Hanauer G. Cardiovascular parameters in anaesthetized guinea pigs: A safety pharmacology screening model. Journal of Pharmacological and Toxicological Methods 2005, 52:106-114.
18. Hussein, L., Davies, M.R., Mistry, H., Pollard, C.E., Swinton, J., Valentin, J.-P., Abi-Gerges, N. (in press). In silico canine cardiac midmyocardial action potential model: Suitable for early assessment? J Pharmacol Toxicol, Proceedings of the 10th Annual Meeting of the Safety Pharmacology Society.
19. Kågström J., Sjogren E.L., Ericson A.C. Evaluation of the guinea pig monophasic action potential (MAP) assay in predicting drug-induced delay of ventricular repolarisation using 12 clinically documented drugs. Journal of Pharmacological and Toxicological Methods 2007, 56:186-193.
20. Kinter L.B., Gossett K.A., Kerns W.D. Status of safety pharmacology in the pharmaceutical industry - 1993. Drug Development Research 1994, 32:208-216.
21. Lindgren S., Bass A.S., Briscoe R., Bruse K., Friedrichs G.S., Kallman M.J., Markgraf C., Patmore L., Pugsley M.K. Benchmarking Safety Pharmacology regulatory packages and best practice. Journal of Pharmacological and Toxicological Methods 2008, 58:99-109.
22. Luft J., Bode G. Integration of safety pharmacology endpoints into toxicology studies. Fundamental and Clinical Pharmacology 2002, 16:91-103.
23. McMahon N., Pollard C., Hammond T.G., Valentin J.P. Cardiovascular Safety Pharmacology. Nonclinical Drug Safety Assessment - Practical Considerations for Successful Registration 2007, 87-123. FDA News, Washington, USA, Chap. 6. W.K. Sietsema, R. Schwen (Eds.).
24. Olson H., Betton G., Robinson D., Thomas K., Monro A., Kolaja G., Lilly P., Sanders J., Sipes G., Bracken W., Dorato M., Van Deun K., Smith P., Berger B., Heller A. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regulatory Toxicology and Pharmacology 2000, 32:56-67.
25. Omata T., Kasai C., Hashimoto M., Hombo T., Yamamoto K. QT PRODACT: comparison of non-clinical studies for drug-induced delay in ventricular repolarization and their role in safety evaluation in humans. Journal of Pharmacological Sciences 2005, 99:531-541.
26. Pugsley M.K., Authier S., Curtis M.J. Principles of safety pharmacology. British Journal of Pharmacology 2008, 154:1382-1399.
27. Pugsley M.K., Authier S., Towart R., Gallacher D.J., Curtis M.J. Beyond the safety assessment of drug-mediated changes in the QT interval...what's next?. Journal of Pharmacological and Toxicological Methods 2009, 60:24-27.
28. Redfern W.S., Bialecki R., Ewart L., Hammond T.G., Kinter L., Lindgren S., Pollard C.E., Rolf M., Valentin J.-P. Impact and prevalence of safety pharmacology-related toxicities throughout the pharmaceutical life cycle. Journal of Pharmacological and Toxicological Methods 2010, 62:e29.
29. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., Siegl P.K.S., Strang I., Sullivan A.T., Wallis R., Camm A.J., Hammond T.G. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovascular Research 2003, 58:32-45.
30. Redfern W.S., Wakefield I.D. Safety Pharmacology. Toxicological Testing Handbook: Principles, Applications and Data Interpretation 2006, Taylor & Francis Ltd. 2nd edn. K. Keller, D. Jacobson-Kram (Eds.).
31. Redfern W.S., Wakefield I.D., Prior H., Pollard C.E., Hammond T.G., Valentin J.-P. Safety pharmacology - a progressive approach. Fundamental and Clinical Pharmacology 2002, 16:161-173.
32. Redfern W.S., Waldron G., Winter M.J., Butler P., Holbrook M., Wallis R., Valentin J.-P. Zebrafish assays as early safety pharmacology screens: Paradigm shift or red herring?. Journal of Pharmacological and Toxicological Methods 2008, 58:110-117.
33. Sterner W., Korn W.D. Zur pharmakologie und toxikologie von etofyllinclofibrate. Arzneimittel-Forschung 1980, 30:2023-2031.
34. Valentin J.-P., Bass A.S., Atrakchi A., Olejniczak K., Kannosuke F. Challenges and lessons learned since implementation of the safety pharmacology guidance ICH S7A. Journal of Pharmacological and Toxicological Methods 2005, 52:22-29.
35. Valentin J.-P., Bialecki R., Ewart L., Hammond T.G., Leishmann D., Lindgren S., Martinez V., Pollard C., Redfern W.S., Wallis R. A framework to assess the translation of safety pharmacology data to humans. Journal of Pharmacological and Toxicological Methods 2009, 60:152-158.
36. Valentin J.-P., Hammond T.G. Safety and secondary pharmacology: Successes, threats, challenges and opportunities. Journal of Pharmacological and Toxicological Methods 2008, 58:77-87.